Evidence reviewed: 22 July 2026 · Author: ExtolX Editorial Team · Scientific review: Pending
Educational information for laboratory research audiences. This article does not provide medical advice, dosage or administration guidance.
CJC-1295-type peptides and ipamorelin act through different upstream receptors in growth-hormone research. Evidence for each compound should be separated from evidence for their combination.
Key points
- The compound is a combination of a growth-hormone-releasing-hormone receptor agonist analogue and the ghrelin-receptor agonist ipamorelin.
- Evidence from cells, animals and humans must be interpreted separately.
- Investigational; no MHRA-authorised combination medicine was identified.
- Research findings do not establish that independently supplied material is equivalent to a clinical-trial product.
What is it?
CJC-1295-type peptides and ipamorelin act through different upstream receptors in growth-hormone research. Evidence for each compound should be separated from evidence for their combination. In scientific work, identity should be established through appropriate analytical documentation rather than inferred from a product name alone.
How is it thought to work?
GHRH-receptor and ghrelin-receptor signalling can converge on pituitary growth-hormone release. The label ‘CJC-1295 No DAC’ is used inconsistently and is not equivalent to albumin-binding CJC-1295 with a drug-affinity complex.
What does the current evidence show?
- Albumin-binding CJC-1295 was studied in small placebo-controlled healthy-adult trials and produced sustained GH and IGF-1 changes.
- Ipamorelin pharmacokinetics and GH responses were characterised in healthy volunteers, and a later Phase 2 trial examined postoperative ileus.
- Controlled human evidence for the precise No-DAC plus ipamorelin combination is sparse.
Evidence snapshot
| Evidence level | What it can establish | Main caution |
|---|---|---|
| Laboratory | Biochemical activity and cellular responses under defined conditions | Does not establish effects in an intact organism |
| Animal | Mechanisms and model-specific biological responses | Translation to humans is uncertain |
| Human | Outcomes in the studied population and formulation | Must not be generalised beyond the actual trial |
What remains unknown?
- Published CJC-1295 data may concern DAC-modified material rather than the marketed No-DAC sequence.
- Biomarker changes do not establish clinical benefit.
- The combination can produce interactions not predicted from studying each component alone.
Regulatory and safety context
Investigational; no MHRA-authorised combination medicine was identified. A research-use label does not override the way a product is presented, promoted or used. Safety information from one formulation or jurisdiction cannot be transferred automatically to another.
Frequently asked questions
Does published research prove a benefit?
No. A finding must be interpreted in the context of its model, study design, population, formulation and endpoints. Preliminary or preclinical findings are not proof of clinical benefit.
Is research material equivalent to material used in a clinical trial?
Not on the basis of a shared name. Equivalence would require evidence concerning identity, manufacture, purity, formulation, stability and biological activity.
References and further reading
Research-use notice: ExtolX products are supplied strictly for legitimate laboratory research. They are not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of disease.